

ACCESS PATHWAYS® PROGRAM

300 PATIENTS SERVED-AND GROWING

Access Pathways[®] Program for VIGADRONE[®]

Since June 2018, the Access Pathways[®] Program for VIGADRONE[®] has helped physicians overcome the obstacles of prescribing vigabatrin. At no additional cost to patients, we provide a dedicated, experienced team that surrounds patients and caregivers with support, in an effort to **shorten time to therapy**.

Please see Important Safety Information, including Boxed Warning for Risk of Permanent Vision Loss, on page 3-4, and accompanying full Prescribing Information.

93%

OF ELIGIBLE PATIENTS

receive starter treatment within 48 hours following referral.¹

2.87 HOURS

Average time to first call attempt with caregiver, in business hours.¹



4.34 HOURS

Average time to first contact with caregiver.¹



4.76 HOURS

Average time to shipment of VIGADRONE®.1



50.68 HOURS

Average time to delivery of prescription VIGADRONE®.¹

SUCCESS STORIES

Access Pathways[®] is fully committed to providing the support patients and caregivers need, regardless of when they need it.



AFTER-HOURS CARE¹

VIGADRONE⁻ was personally delivered to the airport for overnight delivery the same day a patient received their diagnosis.



WEEKEND SUPPORT¹

A Saturday priority overnight delivery of VIGADRONE[®] to a patient caregiver was arrange

Does not include patients who at time of referral are missing REMS or Access Pathways[®] consent, need Rx clarification or opt to not start treatment. CONTACT YOUR REPRESENTATIVE FOR FULL PROGRAM DETAILS







Brand-quality support for you and your patients. Upsher-Smith created the Access Pathways[®] Program to support patients and caregivers and ensure patients receive treatment as quickly as possible.

STEP1 YOUE

YOU ENROLL IN REMS AND PRESCRIBE VIGADRONE®



Complete the Vigabatrin Patient/Parent/Legal Guardian-Physician Agreement Form

Access via a link on VIGADRONE.com. Print, complete and fax form to the Vigabatrin REMS Program at 1-866-205-3072.

Complete the VIGADRONE° Prescription Form

Download the form from VIGADRONE.com. Print, complete and fax form to Access Pathways[®].

Please see Important Safety Information, including Boxed Warning for Risk of Permanent Vision Loss, on page 3-4, and accompanying full Prescribing Information.

STEP 2 WE CONFIRM AND DETERMINE PATIENT COVERAGE

We confirm Step 1 is complete—that both physician and patient Vigabatrin REMS Program documents have been submitted.

We determine if the patient is:

- Covered
- ✓ Not covered or uninsured
- Eligible for the co-pay assistance program
- (··) Or requires a prior authorization

Prior authorization

If the patient requires a prior authorization we contact their insurance provider. We then fax all necessary forms to your office for you to complete. While this is being done, a VIGADRONE[®] starter/bridge supply is sent to the patient. Prior authorization support can be provided only for indicated disease states.

STEP 3 VIGADRONE[®] IS DELIVERED AND TREATMENT CAN BEGIN

Prescription ships to the patient from a specialty pharmacy partner as soon as enrollment and eligibility have been confirmed.

*Does not include patients who at time of referral are missing REMS or Access Pathways® consent, need Rx clarification or opt to not start treatment.





CONTACT ACCESS PATHWAYS®

MONDAY-FRIDAY: 8 am-8 pm EST Phone: 1-866-923-1954 Fax (forms): 1-877-788-4948

WEEKENDS AND AFTER HOURS:

Phone: 1-866-923-1954 Fax (forms): 1-877-827-0395

All forms and additional information is available online at VIGADRONE.com

INDICATIONS

VIGADRONE® (vigabatrin) powder for Oral Solution is indicated for the treatment of: • Infantile Spasms (IS) – monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss.

• Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments and for whom the potential benefits outweigh the potential risk of vision loss; VIGADRONE is not indicated as a first line agent.

IMPORTANT SAFETY INFORMATION

WARNING: PERMANENT VISION LOSS

See full Prescribing Information for complete Boxed Warning.

- VIGADRONE can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases, VIGADRONE may also decrease visual acuity.
- Risk increases with increasing dose and cumulative exposure, but there is no dose or exposure to VIGADRONE known to be free of risk of vision loss.
- Risk of new and worsening vision loss continues as long as VIGADRONE is used, and possibly after discontinuing VIGADRONE.
- Baseline and periodic vision assessment is recommended for patients on VIGADRONE. However, this assessment cannot always prevent vision damage.
- The onset of vision loss from VIGADRONE is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years.
- Because of the risk of permanent vision loss, VIGADRONE is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Vigabatrin REMS Program. Further information is available at www.vigabatrinREMS.com or call 1-866-244-8175.

WARNINGS & PRECAUTIONS

- Permanent Vision Loss. VIGADRONE can cause permanent vision loss. The risk of vision loss increases
 with increasing the dose and cumulative exposure, but there is no dose or exposure known to be free
 of risk of vision loss. Patient response should be periodically assessed. Patients can be affected with
 bilateral concentric visual field constriction ranging in severity from mild to severe. Severe cases may be
 characterized by tunnel vision, which can result in disability. In some cases, VIGADRONE also can damage
 the central retina and may decrease visual acuity. Symptoms of vision loss from VIGADRONE are unlikely
 to be recognized by patients or caregivers before vision loss is severe. Vision loss of milder severity, while
 often unrecognized by the patient or caregiver, can still adversely affect function.
- Monitoring of Vision. Monitoring of vision by an ophthalmic professional with expertise in visual field interpretation and the ability to perform dilated indirect ophthalmoscopy of the retina isrecommended. Because vision testing in infants is difficult, vision loss may not be detected until it is severe. For patients receiving VIGADRONE, vision assessment is recommended at baseline, at least every 3 months while on therapy, and about 3 to 6 months after the discontinuation of therapy. Once detected, vision loss due to VIGADRONE is not reversible. It is expected that even with frequent monitoring, some VIGADRONE patients will develop severe vision loss.
- Magnetic Resonance Imaging (MRI) Abnormalities in Infants. Abnormal MRI signal changes have been
 reported in some infants with Infantile Spasms receiving VIGADRONE. These changes generally resolved
 with discontinuation of treatment.



- Suicidal Behavior and Ideation. Antiepileptic drugs, including VIGADRONE, increase the risk of suicidal
 thoughts and behavior. Patients treated with any AED for any indication should be monitored for the
 emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in
 mood or behavior. Patients, their caregivers, and families should be informed that AEDs increase the risk
 of suicidal thoughts and behavior and should be advised of the need to be alert and report behaviors of
 concern immediately to healthcare providers.
- Neurotoxicity. Based on animal data, VIGADRONE may cause neurotoxicity. Intramyelinic edema (IME), was seen in animals at doses within the human therapeutic range.
- Anemia. VIGADRONE may cause anemia.
- **Somnolence and Fatigue.** VIGADRONE causes somnolence and fatigue. Advise patients not to drive or operate machinery until they have gained sufficient experience on VIGADRONE.
- Peripheral Neuropathy. VIGADRONE causes symptoms of peripheral neuropathy in adults.
- Weight Gain. VIGADRONE causes weight gain in adult and pediatric patients.
- Edema. VIGADRONE causes edema in adults.
- Withdrawal of AEDs. As with all AEDs, VIGADRONE should be withdrawn gradually.

USE IN SPECIFIC POPULATIONS

- Pregnancy: Based on animal data, VIGADRONE may cause fetal harm.
- Nursing Mothers: VIGADRONE is excreted in human milk.

DRUG INTERACTIONS

VIGADRONE may decrease phenytoin plasma levels: dosage adjustment may be needed.

ADVERSE REACTIONS

Refractory Complex Partial Seizures

Most common adverse reactions in controlled studies include (incidence ≥5% over placebo):

- · Adults: blurred vision, somnolence, dizziness, abnormal coordination, tremor, and fatigue
- Pediatric patients (3 to 16 years of age): weight gain
- Infantile Spasms (incidence >5% and greater than on placebo)
- · Somnolence, bronchitis, ear infection, and acute otitis media

The most serious adverse reactions are listed above in the WARNINGS AND PRECAUTIONS section.

Refer to the DOSAGE AND ADMINISTRATION section of the full Prescribing Information for recommended dosing guidelines for VIGADRONE, including specific populations.

This safety information is not comprehensive. Please refer to the <u>full Prescribing Information</u>, including Boxed Warning for vision loss for VIGADRONE, WARNINGS AND PRECAUTIONS and <u>Medication Guide</u>. You can also visit <u>www.vigadrone.com</u>, <u>www.upsher-smith.com</u> or call 1-888-650-3789.

You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting <u>www.fda.gov/medwatch</u>.



References 1. Data on file. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019. _______

VIGADRONE and Access Pathways are registered trademarks of Upsher-Smith Laboratories, LLC. © 2020 Upsher-Smith Laboratories, <u>LLC, 6701 Evenstad Drive, Maple Grove, MN 55369</u>



Partners in Health Since 1919

VIGADRONE® for oral solution

IN0556AU R0220

The dosage may be increased in weekly

Dose patients weighing more than 60 kg according to adult recommendations (2)

(25 mg/kg twice daily); increase total

daily dose every 3 days, in increments of

25 mg/kg/day to 50 mg/kg/day, up to a maximum daily dose of 150 mg/kg

Infantile Spasms Initiate at a daily dose of 50 mg/kg

(75 mg/kg twice daily) (2.3)

---- DOSAGE FORMS AND STRENGTHS-

Powder for Oral Solution: 500 mg (3)

Abnormal MRI signal changes and

---- CONTRAINDICATIONS -----

--- WARNINGS AND PRECAUTIONS -----

intramyelinic edema have been reported

/IGADRONE, increase the risk of suicidal

Withdrawal of AEDs: Taper dose to avoid

Somnolence and fatigue: Advise patients not to drive or operate machinery until they have gained sufficient experience on

in some infants with Infantile Spasms

eceiving vigabatrin (5.3, 5.4)

houghts and behavior (5.5)

Anemia: Monitor for symptoms of

--- ADVERSE REACTIONS-

Refractory Complex Partial Seizures Most common adverse reactions in controlled

Adults: blurred vision, somnolence

tremor, and fatigue (<u>6.1</u>) Pediatric patients (3 to 16 years of age):

Infantile Spasms (incidence >5% and greater

To report SUSPECTED ADVERSE REACTIONS

contact Upsher-Smith Laboratories, LLC at 1-855-899-9180 or FDA at 1-800-FDA-1088

----- DRUG INTERACTIONS

Decreased phenytoin plasma levels: dosage adjustment may be needed $(\underline{7.1})$

-- USE IN SPECIFIC POPULATIONS ·

Lactation: VIGADRONE is excreted in

Pregnancy: Based on animal data, may

FORMATION and Medication Guide. Revised: 02/2020

Antiepileptic Drugs Oral Contraceptives

USE IN SPECIFIC POPULATIONS

Pediatric Use

Geriatric Use

9 DRUG ABUSE AND DEPENDENCE

10.1 Signs, Symptoms, and Laboratory Findings of Overdosage

t of Fertility

Complex Partial Seizures

10.2 Management of Overdosage 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY

12.2 Pharmacodynamics

13.1 Carcinogenesis, Mutag

16 HOW SUPPLIED/STORAGE AND

How Supplied

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed

6.2 Storage and Han

13 NONCLINICAL TOXICOLOGY

14 CLINICAL STUDIES

Mechanism of Action

Abuse

9.3 Dependence 10 OVERDOSAGE

ence, bronchitis, ear infection.

lizziness abnormal coordination

studies include (incidence ≥5% over

and acute otitis media (6.1)

withdrawal seizures (5.6)

nemia (<u>5.7</u>)

VIGADRONE (5.8)

weight gain (<u>6.1</u>)

or www.fda.gov/medwatch

cause fetal harm (8.1)

See 17 for PATIENT COUNSELING

DRUG INTERACTIONS

human milk (8.2)

han on placebo) Somnolence

Suicidal behavior and

Renal Impairment: Dose adjustment

ecommended (<u>2.4</u>, <u>8.5</u>, <u>8.6</u>)

None (4)

intervals, depending on response (2.2)

UICUI ICUTS (F PRESCRIBING
niunciuni s u	IF FRESCRIDING
INFORMATION	

These highlights do not include all the n needed to use VIGAD FOR ORAL SOLUTION safely and effect See full prescribing information for VIGADRONE® FOR ORAL SOLUTION

solution Initial U.S. Approval: 2009 WARNING: PERMANENT VISION LOSS See full prescribing information for

VIGADRONE® (vigabatrin) powder for oral

complete boxed warning. VIGADRONE can cause perm ilateral concentric visual fiel riction, including tunnel visio that can result in disability. In some cases, VIGADRONE may also decreas visual acuity (5.1).

Risk increases with increasing dose and dose or exposure to VIGADRONE know to be free of risk of vision loss (5.1) Risk of new and worsening vision los nues as long as VIGADRONE is and possibly after discontinuin used, and pos ONE (5.1)

Baseline and periodic vision sment is rec patients on VIGADRONE. Howeve sment cannot always prevent vision damage (5.1). VIGADRONE is available only th

a restricted program called the Vigabatrin REMS Program (5.2). -- RECENT MAJOR CHANGES--

Indications and Usage (<u>1.1</u>) 1/2020 Dosage and Administration (<u>2.1, 2.2, 2.4, 2.5</u>) 1/2020 igs and Precau Warnings and Precautions (5.3) Warnings and Precautions (5.4) 7/2019 --INDICATIONS AND USAGE -

VIGADRONE is indicated for the treatment of Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of

age and older who have responded inadequately to several alternative treatments; VIGADRONE is not indicated as a first line agent (1.1)Infantile Spasms - monotherapy in

infants 1 month to 2 years of age for whom the potential benefits of the potential risk of vision loss (1.2

-- DOSAGE AND ADMINISTRATION <u>Refractory Complex Partial Seizures</u>
 Adults (17 years of age and older):

Initiate at 1000 mg/day (500 mg twice ; increase total daily dose 500 mg/day incre ended dose of 3000 mg/day (1500 mg twice daily) (<u>2.2</u>)

Pediatric (2 to 16 years of age): The recommended dosage is based on body weight and administered as two divided

doses (<u>2.2</u>) FULL PRESCRIBING INFORMATION: CONTENTS* RNING: PERMANENT VISION LOSS INDICATIONS AND USAGE Refractory Complex Partial Seizures (CPS)

Infantile Spasms (IS 2 DOSAGE AND ADMINISTRATIO Important Dosing and Administration Inst 2.2 Refractory Complex Partial

2.3 Infantile Spasms Patients with Renal Impai Preparation and Adr

nstructions for VIGADRONE wder for Oral S DOSAGE FORMS AND STRENGTHS

CONTRAINDICATION WARNINGS AND PRECAUTIONS

Vigabatrin REMS Program

5.3 Magnetic Resonance Im (MRI) Abnormalities in Infan

Suicidal Behavior and Ideatio Withdrawal of Antiepileptic Drugs

(AEDs) 5.7 Anemia

Somnolence and Fatio Peripheral Neuropathy

5.10 Weight Gain 5.11 Edema 6 ADVERSE REACTIONS

6.1 Clinical Trial Experience6.2 Post Marketing Experience

FULL PRESCRIBING INFORMATION

WARNING: PERMANENT VISION LOSS VIGADRONE can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases, VIGADRONE also can damage the central retina and may decrease visual acuity [see Warnings and Proceedings (5, 1)] he onset of vision loss from VIGADRONE is unpredictable and can occur within weeks

of starting treatment or sooner, or at any time after starting treatment, even after months or years. Symptoms of vision loss from VIGADRONE are unlikely to be recognized by patients o

caregivers before vision loss is severe. Vision loss of milder severity, while often unrecognized by the patient or caregiver, can still adversely affect function. The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss.

Vision assessment is recommended at baseline (no later than 4 weeks after starting VIGADRONE), at least every 3 months during therapy, and about 3 to 6 months after the

discontinuation of therapy. Once detected, vision loss due to VIGADRONE is not reversible. It is expected that, even with frequent monitoring, some patients will develop severe vision loss. Consider drug discontinuation, balancing benefit and risk, if vision loss is documen

Risk of new or worsening vision loss continues as long as VIGADRONE is used. It is possible that vision loss can worsen despite discontinuation of VIGADRONE. Because of the risk of vision loss, VIGADRONE should be withdrawn from patients with refractory complex partial seizures who fail to show substantial clinical benefit within 3 months of initiation and within 2 to 4 weeks of initiation for patients with infantile

spasms, or sooner if treatment failure becomes obvious. Patient response to and continued need for VIGADRONE should be periodically reassessed. VIGADRONE should not be used in patients with, or at high risk of, other types of

irreversible vision loss unless the benefits of treatment clearly outweigh the risks. VIGADRONE should not be used with other drugs associated with serious adverse ophthalmic effects such as retinopathy or glaucoma unless the benefits clearly outweigh the risks. Use the lowest dosage and shortest exposure to VIGADRONE consistent with clinical

objectives [see Dosage and Administration (2.1)]. Because of the risk of permanent vision loss, VIGADRONE is available only through a

exause of the risk of permanent vision loss, vick brown over is available only diffolign a stricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the igabatrin REMS Program *(see Warnings and Precautions (5.2)*). Further information is railable at www.vigabatrinREMS.com or call 1-866-244-8175. INDICATIONS AND USAGE

In Befractory Complex Partial Seizures (CPS) VIGADRONE is indicated as adjunctive therapy for adults and pediatric patients 2 years of age

and older with refractory complex partial seizures who have inadequately responded to severa alternative treatments and for whom the potential benefits outweigh the risk of vision loss (see Warnings and Precautions (5.1)]. VIGADRONE is not indicated as a first line agent for comple

1.2 Infantile Spasms (IS) VIGADRONE is indicated as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss [see Warnings and Precautions (5.1)1.

DOSAGE AND ADMINISTRATION Important Dosing and Administration Instructions

Dosing Use the lowest dosage and shortest exposure to VIGADRONE consistent with clinical objectives [see Warnings and Precautions (5.1)]. The VIGADRONE dosing regimen depends on the indication, age group, weight, and dosage

form (tablets or powder for oral solution) [see Dosage and Administration (2.2, 2.3)]. Patients with impaired renal function require dose adjustment [see Dosage and Administration (2.4)]. Monitoring of VIGADRONE plasma concentrations to optimize therapy is not helpful. Administration VIGADRONE is given orally with or without food.

IVIGADBONE powder for oral solution should be mixed with water prior to administration [see on (2.5)] A calibrated me and deliver the prescribed dose accurately. A household teaspoon or tablespoon is not a adequate measuring device. If a decision is made to discontinue VIGADRONE, the dose should be gradually reduced [see Dosage and Administration (2.2, 2.3) and Warnings and Precautions (5.6)].

2.2 Refractory Complex Partial Seizures

2.2 Herractory complex Parial Seizures Adults (Patients 17 Years of Age and Older) Treatment should be initiated at 1000 mg/day (500 mg twice daily). Total daily dose may be increased in 500 mg increments at weekly intervals, depending on response. The recommended dose of VIGADRONE in adults is 3000 mg/day (1500 mg twice daily). A 6000 mg/day dose has not been shown to confer additional benefit compared to the 3000 mg/day dose and is exercised with the or isorecard leadence of a downer owner do the 3000 mg/day dose and is associated with an increased incidence of adverse events. In controlled clinical studies in adults with complex partial seizures, vigabatrin was tapered by

easing the daily dose 1000 mg/day on a weekly basis until discontinued [see Warnings and Pediatric (Patients 2 to 16 Years of Age)

he recommended dosage is based on body weight and administered as two divided doses, as shown in Table 1. The dosage may be increased in weekly intervals to the total daily maintenance dosage, depending on response. Pediatric patients weighing more than 60 kg should be dosed according to adult

Table 1. CPS Dosing Recommendations for Pediatric Patients Weighing 10 kg up to 60 $kg^{\dagger\dagger}$

Body Weight [kg]	Total Daily* Starting Dose	Total Daily* Maintenance Dose [†]
[[mg/day]	[mg/day]
10 kg to 15 kg	350 mg	1,050 mg
Greater than 15 kg to 20 kg	450 mg	1,300 mg
Greater than 20 kg to 25 kg	500 mg	1,500 mg
Greater than 25 kg to 60 kg	500 mg	2,000 mg

Administered in two divided dos † Maintenance dose is based on 3000 mg/day adult-equivalent dose ^{††}Patients weighing more than 60 kg should be dosed according to adult recommendation

In natients with refractory complex partial seizures VIGADBONE should be withdrawn if a substantial clinical benefit is not observed within 3 months of initiating treatment. If, in the clinical judgment of the prescriber, evidence of treatment failure becomes obvious earlier than 3 months, treatment should be discontinued at that time [see Warnings and Precautions (<u>5.1</u>)]. In a controlled study in pediatric patients with complex partial seizures, vigabatrin was tapered by decreasing the daily dose by one third every week for three weeks [see Warnings and Precautions (5.6)1. 2.3 Infantile Spasms

The initial daily dosing is 50 mg/kg/day given in two divided doses (25 mg/kg twice daily); subsequent dosing can be titrated by 25 mg/kg/day to 50 mg/kg/day increments every 3 days, up to a maximum of 150 mg/kg/day given in 2 divided doses (75 mg/kg twice daily) [see Use in Specific Populations (8.4)]. Table 2 provides the volume of the 50 mg/mL dosing solution that should be administered as

individual doses in infants of various weights. Table 2. Infant Dosing Table

	Table 2. Infant Dusing Table	
Weight [kg]	Starting Dose 50 mg/kg/day	Maximum Dose 150 mg/kg/day
3	1.5 mL twice daily	4.5 mL twice daily
4	2 mL twice daily	6 mL twice daily
5	2.5 mL twice daily	7.5 mL twice daily
6	3 mL twice daily	9 mL twice daily
7	3.5 mL twice daily	10.5 mL twice daily
8	4 mL twice daily	12 mL twice daily
9	4.5 mL twice daily	13.5 mL twice daily
10	5 mL twice daily	15 mL twice daily
11	5.5 mL twice daily	16.5 mL twice daily
12	6 mL twice daily	18 mL twice daily
13	6.5 mL twice daily	19.5 mL twice daily
14	7 mL twice daily	21 mL twice daily
15	7.5 mL twice daily	22.5 mL twice daily
16	9 ml twice daily	24 mL twice daily

8 mL twice daily 24 mL twice daily In patients with infantile spasms, VIGADRONE should be withdrawn if a substantial clinical benefit is not observed within 2 to 4 weeks. If, in the clinical judgment of the prescriber, evidence of treatment failure becomes obvious earlier than 2 to 4 weeks, treatment should be discontinued at that time [see Warnings and Precautions (<u>5.1</u>)].

In a controlled clinical study in patients with infantile spasms, vigabatrin was tapered by decreasing the daily dose at a rate of 25 mg/kg to 50 mg/kg every 3 to 4 days [see Warnings and Precautions (5.6)].

2.4 Patients with Renal Impairment VIGADRONE is primarily eliminated through the kidney

on about how to adjust the dose in infants with renal impairment is unavailable

Adult and pediatric patients 2 years and older Mild renal impairment (CLcr >50 to 80 mL/min): dose should be decreased by 25% Moderate renal impairment (CLcr >30 to 50 mL/min): dose should be decreased by

Severe renal impairment (CLcr >10 to 30 mL/min): dose should be decreased by 75% CLcr in mL/min may be estimated from serum creatinine (mg/dL) using the following formulas:
 Patients 2 to <12 years old: CLcr (mL/min/1.73 m²) = (K × Ht) / Scr height (Ht) in cm; serum creatinine (Scr) in mg/dL

(proportionality constant): Female Child (<12 years): K=0.55: Male Child (<12 years): K=0.70

 $\begin{array}{l} (1 < y \ cars), \ r = y \ cars),$ The effect of dialysis on VIGADRONE clearance has not been adequately studied [see Clinical Pharmacology (12.3) and Use in Specific Populations (8.6)].

2.5 Preparation and Administration Instructions for VIGADRONE Powder for Oral Solution If using VIGADRONE powder for oral solution, physicians should review and discuss the Medication Guide and instructions for mixing and giving VIGADRONE with the patient or caregiver(s). Physicians should confirm that patients or caregiver(s) understand how to mix VIGADRONE powder with water and administer the correct daily dose.

Empty the entire contents of each 500 mg packet into a clean cup, and dissolve in 10 mL of cold or room temperature water per packet. Administer the resulting solution using the 3 mL or 10 mL oral syringe provided by the pharmacy [see How Supplied/Storage and Handling (<u>16.1</u>)]. The concentration of the final solution is 50 mg/ml

Table 3 below describes how many packets and how many milliliters (mL) of water will be needed to prepare each individual dose. The concentration after reconstitution is 50 mg/mL Table 3. Number of VIGADRONE Packets and mL of Water Needed for Each Individual Dose

Individual Dose [mg] [Given Twice Daily]	Total Number of VIGADRONE Packets	Total mL of Water Required for Dissolving
0 to 500	1 Packet	10 mL
501 to 1,000	2 Packets	20 mL
1,001 to 1,500	3 Packets	30 mL

Discard the resulting solution if it is not clear (or free of particles) and colorless. Each individual dose should be prepared and used immediately. Discard any unused portion of the solution after dministering the correct dose

DOSAGE FORMS AND STRENGTHS mg packets of a white to off-white granular powder

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS Permanent Vision Loss

VIGADRONE can cause permanent vision loss. Because of this risk and because, when it is effective, VIGADRONE provides an observable symptomatic benefit; patient response and

ontinued need for treatment should be periodically assessed. Based upon adult studies, 30 percent or more of patients can be affected with bilateral concervisual field constriction ranging in severity from mild to severe. Severe cases may be characterized by tunnel vision to within 10 degrees of visual fixation, which can result in disability. In some cases, VIGADRONE also can damage the central retina and may decrease visual acuity. Symptoms of vision loss from VIGADRONE are unlikely to be recognized by

atients or caregivers before vision loss is severe. Vision loss of milder severity, while ofter nrecognized by the patient or caregiver, can still adversely affect function. Recause assessing vision may be difficult in infants and children, the frequency and extent of vision loss is poorly characterized in these patients. For this reason, the understanding of the risk is primarily based on the adult experience. The possibility that vision loss from VIGADRONE may be more common, more severe, or have more severe functional consequences in infants

and children than in adults cannot be excluded. The onset of vision loss from VIGADRONE is unpredictable and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years.

The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss. In patients with refractory complex partial seizures, VIGADRONE should be withdrawn if a ubstantial clinical benefit is not observed within 3 months of initiating treatment. If, in the

clinical judgment of the prescriber, evidence of treatment failure becomes obvious earlier than 3 months, treatment should be discontinued at that time [see Dosage and Administration (2,2) and Warnings and Precautions (5,6)]. In patients with infantile spasms, VIGADRONE should be withdrawn if a substantial clinical

benefit is not observed within 2 to 4 weeks. If, in the clinical judgment of the prescriber, evidence of treatment failure becomes obvious earlier than 2 to 4 weeks, treatment should be liscontinued at that time [see Dosage and Administration (2.3) and Warnings and Precautions

VIGADRONE should not be used in patients with, or at high risk of, other types of irreversible vision loss unless the benefits of treatment clearly outweigh the risks. The interaction of other types of irreversible vision damage with vision damage from VIGADRONE has not been wellcharacterized, but is likely adverse.

VIGADRONE should not be used with other drugs associated with serious adverse ophthalmic effects such as retinopathy or glaucoma unless the benefits clearly outweigh the risk

Monitoring of Vision Monitoring of vision by an ophthalmic professional with expertise in visual field interpretation and the ability to perform dilated indirect ophthalmoscopy of the retina is recommended [see Warnings and Precautions (5.2)]. Because vision testing in infants is difficult, vision loss may not be detected until it is severe. For patients receiving VIGADRONE, vision assessment is commended at baseline (on later than 4 weeks after starting VIGADRONE), at least every months while on therapy, and about 3 to 6 months after the discontinuation of therapy. The iagnostic approach should be individualized for the patient and clinical situation.

In adults and cooperative pediatric patients, perimetry is recommended, preferably by automated hreshold visual field testing. Additional testing may also include electrophysiology (e.g., lectroretinography [ERG]), retinal imaging (e.g., optical coherence tomography [OCT]), and/or other methods appropriate for the patient. In patients who cannot be tested, treatment may continue according to clinical judgment, with approvide patient courseling. Because of variability, results from ophthalmic monitoring must be interpreted with caution, and repeat assessment is recommended if results are abnormal or uninterpretable. Repeat assessment in the first few weeks of treatment is recommended to establish if, and to what degree, reproducible results can be obtained, and to guide selection of appropriate ongoing monitoring

for the patient. The onset and progression of vision loss from VIGADRONE is unpredictable, and it may occur or worsen precipitously between assessments. Once detected, vision loss due to VIGADRONE is not reversible. It is expected that even with frequent monitoring, some VIGADRONE patients will develop severe vision loss. Consider drug discontinuation, balancing benefit and risk, if vision loss is documented. It is possible that vision loss can worsen despite discontinuation of VIGADRONE.

5.2 Vigabatrin REMS Program RONE is available only through a restricted distribution program called the Vigabatrin REMS Program, because of the risk of permanent vision loss

Notable requirements of the Vigabatrin REMS Program include the following: Prescribers must be certified by enrolling in the program, agreeing to counsel patients on the risk of vision loss and the need for periodic monitoring of vision, and reporting any event suggestive of vision loss to www.vigabatrinREMS.com

Patients must enroll in the program Pharmacies must be certified and must only dispense to patients authorized to receive VIGADRONE

Further information is available at www.vigabatrinREMS.com or call 1-866-244-8175 5.3 Magnetic Resonance Imaging (MRI) Abnormalities in Infants Abnormal MRI signal changes characterized by increased T2 signal and restricted diffusion in a symmetric pattern involving the thalamus, basal ganglia, brain stem, and cerebellum have been observed in according to traded with vieobstrict.

served in some infants treated with vigabatrin. In a retrospective epidemiologic study in infants with infantile spasms (N=205), the prevalence of MRI changes was 22% in vigabatrin-treated patients versus 4% in patients treated with other therapies. In this study, in post-marketing experience, and in published literature reports, these changes generally resolved with discontinuation of treatment. In a few patients, the lesion olved despite continued use. It has been reported that some infants exhibited coincident motor abnormalities, but no causal relationship has been established and the potential for ong-term clinical sequelae has not been adequately studied.

Neurotoxicity (brain histopathology and neurobehavioral abnormalities) was observed in rats exposed to vigabatrin during late gestation and the neonatal and juvenile periods of development and brain histopathological changes were observed in dogs exposed to vigabatrin during the juvenile period of development. The relationship between these findings and the abnormal MRI indings in infants treated with vigabatrin for infantile spasms is unknown [see Warnings and tions (5.4) and Use in Specific Populations (8.1)]. The specific pattern of signal changes observed in patients 6 years and younger was not observed in older pediatric and adult patients treated with vigabatrin. In a blinded review of MRI images obtained in prospective clinical trials in patients with refractory complex partial seizures (2002) where the MCCO with the second sec

(CPS) 3 years and older (N=656), no difference was observed in anatomic distribution or prevalence of MRI signal changes between vigabatrin treated and placebo treated patients. In the post-marketing setting, MRI changes have also been reported in patients 6 years of age and unger being treated for refractory CPS. For adults treated with VIGADRONE, routine MRI surveillance is unnecessary as there is no evidence that vigabatrin causes MRI changes in this population.

5.4 Neurotoxicity velinic Edema (IME) has been reported in postmortem examination of infants being

treated for infantile spasms with vigabatrin. Abnormal MRI signal changes characterized by increased T2 signal and restricted diffusion in a symmetric pattern involving the thalamus, basal ganglia, brain stem, and cerebellum have also been observed in some infrants treated for IS with vigobatrin. Studies of the effects of vigobatrin on MRI and evoked potentials (EP) in adult epilepsy patients have demonstrated no clear-cut abnormalities [see Warnings and Precautions (5.3)]

Vacuolation, characterized by fluid accumulation and separation of the outer layers of myelin has been observed in brain white matter tracts in adult and juvenile rats and adult mice, dogs, and possibly monkeys following administration of vigabatrin. This lesion, referred to as intramyelinic edema (IME), was seen in animals at doses within the human therapeutic range. A no-effect dose was not established in rodents or dogs. In the rat and dog, vacuolation was reversible following discontinuation of vigabatrin treatment, but, in the rat, pathologic changes sisting of swollen or degenerating axons, mineralization, and gliosis were seen in brain areas n which vacuolation had been previously observed. Vacuolation in adult animals was correlated with alterations in MRI and changes in visual and somatosensory EP.

Administration of vigabatrin to rats during the neonatal and juvenile periods of development produced vacuolar changes in the brain gray matter (including the thalamus, midbrain, deep cerebellar nuclei, substantia nigra, hippocampus, and forebrain) which are considered distinct from the IME observed in vigabatrin-treated adult animals. Decreased myelination and evidence of oligodendrocyte injury were additional findings in the brains of vigabatrin-treated rats. An increase in apoptosis was seen in some brain regions following vigabatrin exposure during the early postnatal period. Long-term neurobehavioral abnormalities (convulsions, neuromotor impairment, learning deficits) were also observed following vigabatrin treatment of young rats. Administration of vigabatrin to juvenile dogs produced vacuolar changes in the brain gray matter (including the septal nuclei, hippocampus, hypothalamus, thalamus, cerebellum, and globus nallidus) Neurobehavioral effects of vigabatrin were not assessed in the invenile dog. These effects in young animals occurred at doese lower than those producing neurotoxicity in adult animals and were associated with plasma vigabatrin levels substantially lower than those achieved clinically in infants and children [see Use in Specific Populations (<u>8.1, 8.4</u>)]. In a published study, vigabatrin (200, 400 mg/kg/day) induced apoptotic neurodegen the brain of young rats when administered by intraperitoneal injection on postnatal days 5 to 7

Administration of vigabatrin to female rats during pregnancy and lactation at doses below those used clinically resulted in hippocampal vacuolation and convulsions in the mature offspring

5.5 Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including VIGADRONE, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of In different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 10 works the settimated to a consistence on the suicidal theories and edian treatment duration of 10 works the settimated to placebo. 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients esenting an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one

ssessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk

The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did action understand the super (54 to 20 super) in the distinct action and across a super super super terms of the distinct action and across a super supe

did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Table 4 shows

Table 4. Risk by Indication for Antiepileptic Drugs in the Pooled Analysis

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in

clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for

Anyone considering prescribing VIGADRONE or any other AED must balance the risk of suicidal

upths or behavior with the risk of untreated illness. Epilepsy and many other illnesses for nich AEDs are prescribed are themselves associated with morbidity and mortality and an reased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge

during treatment, the prescriber needs to consider whether the emergence of these symptoms in

Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal

raterist, their cleavers, and should be advised of the need to be alert for the emergence or worsening of the signs and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

s with all AEDs, VIGADRONE should be withdrawn gradually. However, if withdrawal is needed ecause of a serious adverse event, rapid discontinuation can be considered. Patients and aregivers should be told not to suddenly discontinue VIGADRONE therapy.

controlled clinical studies in adults with complex partial seizures, vigabatrin was tapered by

In a controlled study in pediatric patients with complex partial seizures, vigabatrin was tapered

5.7 Anemia In North American controlled trials in adults, 6% of patients (16/280) receiving vigabatrin and

2% of patients (3/188) receiving placebo had adverse events of anemia and/or met criteria for

potentially clinically important hematology changes involving hemoglobin, hematocrit, and/or RBC indices. Across U.S. controlled trials, there were mean decreases in hemoglobin of about

3% and 0% in vigabatrin and placebo-treated patients, respectively, and a mean decrease in hemotical decrease in hematocrit of about 1% in vigabatrin-treated patients compared to a mean gain of about 1% in patients treated with placebo.

(0.06%, 3/4,855) discontinued for anemia and 2 vigabatrin patients experienced unexplained

VIGADRONE causes somnolence and fatigue. Patients should be advised not to drive a ca operate other complex machinery until they are familiar with the effects of VIGADRONE o ability to perform such activities.

Pooled data from two vigabatrin controlled trials in adults demonstrated that 24% (54/222) of

vigabatrin patients experienced somolocic main in domain and the semicircular trans (4/122) of vigabatrin patients experienced somolocic compared to 10% (14/123) of placebo patients. In those same studies, 28% of vigabatrin patients experienced fatigue compared to 15% (20/135) of placebo patients. Almost 1% of vigabatrin patients discontinued from clinical trials for somnolence and almost 1% discontinued for fatigue.

Pooled data from three vigabatrin controlled trials in pediatric patients demonstrated that 6%

compared to 7% (7/104) of placebo patients. No vigabatrin patients discontinued from clinical

5.9 Peripheral Neuropathy Vigabatrin causes symptoms of peripheral neuropathy in adults. Pediatric clinical trials were not designed to assess symptoms of peripheral neuropathy but observed incidence of symptoms based on pooled data from controlled pediatric studies appeared similar for pediatric patients on

pabatrin and placebo. In a pool of North American controlled and uncontrolled epilepsy studies,

A2% (19/457) of vigabatrin patients developed signs and/or symptoms of peripheral neuropathy. In the subset of North American placebo-controlled epilepsy trials, 1.4% (4/280) of vigabatrin treated patients and no (0/188) placebo patients developed signs and/or symptoms of patients developed signs and/or symptoms.

lower limb vibration or position sensation, or progressive loss of reflexes, starting at the ankles.

Clinical studies in the development porgram were not designed to investigate peripheral neuropathy systematically and did not include nerve conduction studies, quantitative sensory testing, or skin or nerve biopsy. There is insufficient evidence to determine if development of these signs and symptoms was related to duration of vigabatrin treatment, cumulative dose, or if

the findings of peripheral neuropathy were completely reversible upon discontinuation of

Data pooled from randomized controlled trials in adults found that 17% (77/443) of vigabatrin patients versus 8% (22/275) of placebo patients gained \geq 7% of baseline body weight. In these same trials, the mean weight change among vigabatrin patients was 3.5 kg compared to 1.6 kg

partial seizures found that 47% (77/163) of vigabatrin patients versus 19% (19/102) of placebo patients gained ≥7% of baseline body weight.

In all epilepsy trials, 0.6% (31/4,855) of vigabatrin patients discontinued for weight gain. The long-term effects of vigabatrin related weight gain are not known. Weight gain was not related to

IGADRONE causes edema in adults. Pediatric clinical trials were not designed to assess edema

but observed incidence of edema-based pooled data from controlled pediatric studies appeared

compared to placebo patients for peripheral edema (vigabatrin 2%, placebo 1%), and edema

edema and cardiovascular adverse events such as hypertension or congestive heart failure. Edema was not associated with laboratory changes suggestive of deterioration in renal or hepatic

discontinued for an edema related AE. In adults, there was no apparent association between

Pooled data from controlled trials demonstrated increased risk among vigabatrin patients

(vigabatrin 1%, placebo 0%). In these studies, one vigabatrin and no placebo patients

Data pooled from randomized controlled trials in pediatric patients with refractory complex

VIGADRONE causes weight gain in adult and pediatric patients.

nilar for pediatric patients on vigabatrin and placebo.

ripheral neuropathy. Initial manifestations of peripheral neuropathy in these trials included, in me combination, symptoms of numbness or tingling in the toes or feet, signs of reduced distal

(10/165) of vigabatrin patients experienced somnolence compared to 5% (5/104) of placebo patients. In those same studies, 10% (17/165) of vigabatrin patients experienced fatigue

trolled and open-label epilepsy trials in adults and pediatric patients, 3 vigabatrin patients

nce and fatique. Patients should be advised not to drive a car or

decreasing the daily dose 1000 mg/day on a weekly basis until discontinue

asing the daily dose at a rate of 25 to 50 mg/kg every 3 to 4 days

declines in hemoglobin to below 8 g/dL and/or hematocrit below 24%.

5.8 Somnolence and Fatigue

trials due to somnolence or fatigue.

5.10 Weight Gain

for placebo patients.

the occurrence of edema.

5.11 Edema

d clinical study in nationts with infantile snasme, vigable

by decreasing the daily dose by one third every week for three weeks

Relative Risk

Placebo Patients

3.5

1.5

1.9

1.8

Risk Diffe

with Events pe

1,000 Patients

2.4

2.9

0.9

1.9

week after starting drug treatment with AEDs and persisted for the duration of treatment

Placebo Patients Drug Patients Incidence of Drug with Events per with Events per Events in Drug

3.4

1.8

of suicidal thoughts or behavior beyond 24 weeks could not be assessed

absolute and relative risk by indication for all evaluated AEDs.

1.0

the epilepsy and psychiatric indications.

1.0

with Events per with Events per

5.7 8.5

2.4 4.3

any given patient may be related to the illness being treated.

5.6 Withdrawal of Antiepileptic Drugs (AEDs)

1,000 Patients | 1,000 Patients | Pa

Indication

Epilepsy

sychiatric

and otherwise important adverse reactions are described elsewhere in Permanent Vision Loss [see <u>BOXED WARNING</u> and Warnings and Precautions (Magnetic Resonance Imaging (MRI) Abnormalities in Infants [see Warnings and

Precautions (3.3) Neurotoxicity [see Warnings and Precautions (5.4)] Suicidal Behavior and Ideation [see Warnings and Precautions (5.5)] Withdrawal of Antiepileptic Drugs (AEDs) [see Warnings and Precautions (5.6)] Anemia [see Warnings and Precautions (5.2)] Somnolence and Fatigue [see Warnings and Precautions (5.8)] Peripheral Neuropathy [see Warnings and Precautions (5.9)] Whight Coile (see Warnings and Precautions (5.9)]

ADVERSE REACTIONS

Weight Gain Isee Warnings and Precautions (5.10)1

Edema [see Warnings and Precautions (5.11)]

vision, diplopia, vomiting, influenza, pyrexia, and rash.

≥1% of patients were convulsion and depression.

Refractory Complex Partial Seizures

Body System

Ear Disorders

Tinnitus

Vertiao

Eye Disorders

Diplopia

Eye pain

Nausea

Vomiting

Constipation

Dyspepsia

Toothache

Asthenopia

Gastrointestinal Disorder

Upper abdominal pair

Stomach discomfor

Abdominal pain

Abdominal disten

General Disorders

Gait disturbance

Edema peripheral

Fatique

Asthenia

Chest pain

Thirst

Malaise

Infections

Influenza

Bronchitis

Contusion

Joint sprair

Muscle strain

Wound secretion

Increased appetite

Musculoskeletal Disorde

Weight gain

Arthralgia

Back pain

Myalgia

Headache

Dizziness

Tremor

Nystagmus

Hyporeflexia

Paraesthesia

Hyperreflexia

Hypoaesthesia

Status epilepticu

Lethargy

Sedation

Dysarthria

Postictal state

Sensory loss

Irritability

Depression

Anxiety

Psychiatric Disorder

Confusional state

Depressed mood

Abnormal thinking

Abnormal behavior

Abnormal dreams

Reproductive System

Dysmenorrhea

Couah

Body System

Eve Disorders

Diplopia

Blurred vision

Constipation

General Disorders

Fatigue

Influenza

Investigations

Weight gain

Somnolence

Tremor

Nystagmus

Status epilepticus

Otitis media

Gastrointestinal Disorders

Upper abdominal pain

Infections and Infestation

Streptococcal pharyngitis

Viral gastroenteritis

Nervous System Disorder

Upper respiratory tract infection

Adverse Reactio

Erectile dysfunction

Pharyngolaryngeal pain

Pulmonary congestion

Pediatrics 3 to 16 years of age

Sinus headache

Expressive language disorde

Respiratory and Thoracic Disorders

Skin and Subcutaneous Tissue Disorders

able 6 lists adverse reactions from controlled clinical studies of pediatric patients receiving

vigabatrin or placebo as adjunctive therapy for refractory complex partial seizures. Adverse reactions that are listed occurred in at least 2% of vigabatrin-treated patients and more frequen

Table 6. Adverse Reactions in Pooled. Adjunctive Trials in Pediatric Patients

3 to 16 Years of Age with Refractory Complex Partial Seizures

All VIGADRONE

[N=165]

%

[N=104]

%

than placebo. The median vigabatrin dose was 49.4 mg/kg (range of 8.0 to 105.9 mg/kg).

Somnolence

Pain in extremity

Muscle twitching

Nervous System Disorde

Memory impairment

Abnormal coordination

Disturbance in attention

Sensory disturbance

Muscle spasms

Injury

Nasopharyngiti

Urinary tract infection

Upper respiratory tract infection

Metabolism and Nutrition Disorder

Fever

Blurred vision

Adverse Reaction

Precautions (5.3)1

6 1 Clinical Trial Experience

because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In U.S. and primary non-U.S. clinical studies of 4,079 vigabatrin-treated patients, the most on (≥5%) adverse reactions associated with the use of vigabatrin in combination with

common (20%) average reactions associated with the basic of vigualatin the combination with the provided the comparison of the AEDs were headaches, somnolence, fatigue, dizziness, convulsion, nasopharyngitis, weight gain, upper respiratory tract infection, visual field defect, depression, tremor, nystagmus, nausea, diarrhea, memory impairment, insomnia, irritability, abnormal coordination, blurred wise distinguishes were the some the source of th The adverse reactions most commonly associated with vigabatrin treatment discontinuation in In patients with infantile spasms, the adverse reactions most commonly associated with

pabatrin treatment discontinuation in ≥1% of patients were infections, status epilepticu velopmental coordination disorder, dystonia, hypotonia, hypertonia, weight gain, and Table 5 lists the adverse reactions that occurred in >2% and more than one nation per

vigabatrin-treated group and that occurred more frequently than in placebo patients from 2 U.S. adjunctive clinical studies of refractory CPS in adults. Table 5. Adverse Reactions in Pooled, Adjunctive Trials in Adults with **Refractory Complex Partial Seizures**

Vigabatrin dosage

(mg

[N=134]

n dosage /day)		Infectio
6,000	Placebo	_ Uppe
[N=43]	[N=135]	Otitis
%	%	Viral
		Pneu
0	1	Cand
5	1	Ear ii
		Gast
16	5	Sinus
16	3	Urina
2	0	Influe
5	0	Crou
		Metabo
16	7	Decr
2	8	Nervou
9	6	Seda
5	3	Som
5	1	Statu
5	3	Letha
2	1	Conv
2	1	Нуро
5	2	Psychia
0	1	Irrita
•		Insor
40	16	Respira
12	7	Nasa
7	1	
7	1	Coug Skip op
7	3	Skin an Disorde
5	1	Rash
0	0	
5	0	6.2 F The follo
0	Ŭ	Because
9	10	always p
9	6	exposur
7	4	<u>Birth De</u> hemang
5	0	malform
5	1	anticonv
5		low set (
5	2	<u>Ear Diso</u> Endocrii
2	1	Gastroin
2	1	General
	0	failure
2	U	<u>Hepatob</u>
F		Nervous
5	1	myoclor
14	3	Psychiat psychot
-		Respirat
5	3	Skin and
7	2	Stevens
2	4	7 0
5	1	7.1 A
9	1	<u>Phenyto</u> Althougl
0	1	should b
		in total p
26	31	Clonaze
26	13	VIGADR
26	17	clonazer
19	9	Other Al There ar
16	8	phenoba
16	3	clorazep
16	2	of vigab
		72 0

23

14

14

/5 1)1		/-	, -
(<u>5.1</u>)] d	Psychiatric Disorders		
	Abnormal behavior	7	6
	Aggression	6	2
1	Disorientation	3	0
	Safety of VIGADRONE for the treatment of the similar to pediatric patients 3 to 16		ears of age is expected

Body System

Infantile Spasms In a randomized, placebo-controlled IS study with a 5 day double-blind treatment phase (n=40), the adverse reactions that occurred in >5% of patients receiving vigabatin and that occurred mean forewards there is include a double-blind ware prepared with the form and that occurred nore frequently than in placebo patients were somnolence (vigabatrin 45%, placebo 30% bronchitis (vigabatrin 30%, placebo 15%), ear infection (vigabatrin 10%, placebo 5%), and acute otitis media (vigabatrin 10%, placebo 0%).

All VIGADRON

[N=165]

Placebo

[N=104]

a dose response study of low-dose (18 to 3 8 mg/kg/day) vigabatrin, no clear correlatio s observed. The adverse reactions (≥5% in	n between dose and inci	dence of adverse reactions
able 7. Adverse Reactions in a Placebo-O	Controlled Trial in Patie	nts with Infantile Spasms
dy System Adverse Reaction	Vigabatrin Low Dose [N=114] %	Vigabatrin High Dose [N=108] %
e Disorders (other than field or acuity cha	, -	,,,
Strabismus	5	5
Conjunctivitis	5	2
strointestinal Disorders	Ŭ	-
Vomitina	14	20
Constipation	14	12
Diarrhea	13	12
neral Disorders	10	12
Fever	29	19
ections	23	13
Upper respiratory tract infection	51	46
Otitis media	44	30
Viral infection	20	
Pneumonia	13	19 11
Candidiasis	8	3
Ear infection	7	14
Gastroenteritis viral	6	5
Sinusitis	5	9
Urinary tract infection	5	6
Influenza	5	3
Croup infectious	5	1
etabolism and Nutrition Disorders		
Decreased appetite	9	7
rvous System Disorders		
Sedation	19	17
Somnolence	17	19
Status epilepticus	6	4
Lethargy	5	7
Convulsion	4	7
Hypotonia	4	6
ychiatric Disorders		
Irritability	16	23
Insomnia	10	12
spiratory Disorders		
Nasal congestion	13	4
Cough	3	8
in and Subcutaneous Tissue sorders	-	-

Post-Marketing Experienc

owing adverse reactions have been identified during post-approval use of vigabate these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug e. Adverse reactions are categorized by system organ class

efects: Congenital cardiac defects, congenital external ear anomaly, congenita oma, congenital hydronephrosis, congenital male genital malformation, congenital oral nation, congenital vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal vulsant syndrome, hamartomas, hip dysplasia, limb malformation, limb reduction defect, ears, renal aplasia, retinitis pigmentosa, supernumerary nipple, talipes orders: Deafness

ine Disorders: Delayed puberty testinal Disorders: Gastrointestinal hemorrhage, esophagitis

Disorders: Developmental delay, facial edema, malignant hyperthermia, multi-organ

biliary Disorders: Cholestasis <u>s System Disorders</u>: Dystonia, encephalopathy, hypertonia, hypotonia, muscle spasticity, nus, optic neuritis, dyskinesia

ric Disorders: Acute psychosis, apathy, delirium, hypomania, neonatal agitation

tory Disorders: Laryngeal edema, pulmonary embolism, respiratory failure, stridor <u>d Subcutaneous Tissue Disorders</u>: Angioedema, maculo-papular rash, pruritus, s-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), alopecia

DRUG INTERACTIONS pileptic Drugs

h phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin be considered if clinically indicated, since VIGADRONE may cause a moderate reduction phenytoin plasma levels [see Clinical Pharmacology (12.3)]

RONE may moderately increase the C_{max} of clonazepam resulting in an increase of -associated adverse reactions [see Clinical Pharmacology (12.3)].

are no clinically significant pharmacokinetic interactions between vigabatrin and either barbital or sodium valproate. Based on population pharmacokinetics, carbamazepine, pate, primidone, and sodium valproate appear to have no effect on plasma concentrations patrin [see Clinical Pharmacology (<u>12.3</u>)].

7.2 Oral Contracentives inlikely to affect the efficacy of steroid oral contraceptives [see Clinical

Pharmacology (<u>12.3</u>)]. 7.3 Drug-Laboratory Test Interactions RONE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. Th suppression of ALT and AST activity by VIGADRONE may preclude the use of these markers

especially ALT, to detect early hepatic injury. VIGADRONE may increase the amount of amino acids in the urine, possibly leading to a false positive test for certain rare genetic metabolic diseases (e.g., alpha aminoadipic aciduria).

8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy

Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AEDs, including VIGADRONE, during pregnancy. Encourage women who are taking VIGADRONE during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll-free number 1-888-233-2334 or visiting the ebsite, http://www.aedpregnancyregistry.org/. This must be done by the patient herse

Risk Summary here are no adequate data on the developmental risk associated with the use of VIGADRONE in pregnant women. Limited available data from case reports and cohort studies pertaining to /IGADRONE use in pregnant women have not established a drug-associated risk of major birth riage, or adverse maternal or fetal outcomes. However, based on animal data, VIGADRONE use in pregnant women may result in fetal harm.

When administered to pregnant animals, vigabatrin produced developmental toxicity, including an increase in fetal malformations and offspring neurobehavioral and neurohistopathological effects, at clinically relevant doses. In addition, developmental neurotoxicity was observed in rats treated with vigabatrin during a period of postnatal development corresponding to the third rimester of human pregnancy (see Data). In the LLS general nonulation, the estimated background risk of major birth defects and

miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.

<u>Data</u> Animal Data Administration of vigabatrin (oral doses of 50 to 200 mg/kg/day) to pregnant rabbits throughou

Administration of vigabatine (or a doses of 50 to 200 mg/kg/day) to pregnant rabotis throughout the period of organogenesis was associated with an increased incidence of malformations (cleft palate) and embryofetal death; these findings were observed in two separate studies. The no-effect dose for adverse effects on embryofetal development in rabbits (100 mg/kg/day) is approximately ½ the maximum recommended human dose (MRHD) of 3 g/day on a body surface area (mg/m²) basis. In rats, or al administration of vigabatrin (50, 100, or 150 mg/kg/ day) throughout organogenesis resulted in decreased fetal body weights and increased incidences of fetal anatomic variations. The no-effect dose for adverse effects on embryo-fetal Incluences of relation of variations. The normalized use for adverse enters of entrusts of entrusts of entrusts of adverse for rotoxicity in rats was not established; the low-effect dose (50 mg/kg/day) is approximately 1 the MRHD on a mg/m² basis.

In a published study, vigabatrin (300 or 450 mg/kg) was administered by intraperitoneal injection to a mutant mouse strain on a single day during organogenesis (day 7, 8, 9, 10, 11, or 12). An increase in fetal malformations (including cleft palate) was observed at both doses. Oral administration of vigabatrin (5, 15, or 50 mg/kg/day) to young rats during the neonatal and juvenile periods of development (postnatal days 4 to 65) produced neurobehavioral (convulsions, neuromotor impairment, learning deficits) and neurohistopathological (brain consistence, neuronator implanting, realing outcome denote the program logger denotes and a second and the second second and the second second second and the second secon

(5 mg/kg/day) was associated with plasma vigabatrin exposures (AUC) less than 1/30 of those neasured in pediatric patients receiving an oral dose of 50 mg/kg. 8.2 Lactation **Risk Summary**

Vigabatrin is excreted in human milk. The effects of VIGADRONE on the breastfed infant and on wilk production are unknown. Because of the potential for serious adverse reactions from vigabatrin in nursing infants, breastfeeding is not recommended. If exposing a breastfed infant to VIGADRONE, observe for any potential adverse effects [see Warnings and Precautions (<u>5.1</u>, 5.3, 5.4, 5.8)]. 8.4 Pediatric Use

The safety and effectiveness of VIGADRONE as adjunctive treatment of refractory complex partia The sately and enectiveness of violation of a distribution of the antibility complex partial secures in pediatric patients 2 to 16 years of age have been established and is supported by three double-blind, placebo-controlled studies in patients 3 to 16 years of age, adequate and well-controlled studies in adult patients, pharmacokinetic data from patients 2 years of age and

older, and additional safety information in patients 2 years of age [see Clinical Pharmacol (12.3) and Clinical Studies (14.1)]. The dosing recommendation in this population varies (<u>12.5</u>) and *Chincal studies* (<u>14.7</u>). The dosing recommendation in this pupulation varies according to age group and is weight-based [*see Dosage and Administration* (<u>2.2</u>)]. Adverse reactions in this pediatric population are similar to those observed in the adult population [*see Adverse Reactions* (<u>6.1</u>)]. The safety and effectiveness of VIGADRONE as monotherapy for pediatric patients with infantile spasms (<u>1 month</u> to 2 years of age) have been established [*see Vielden Vie*

Dosage and Administration (<u>2.3</u>) and Clinical Studies (14.2)

Safety and effectiveness as adjunctive treatment of refractory complex partial seizures in pediatric patients below the age of 2 and as monotherapy for the treatment of infantile spasms in pediatric patients below the age of 1 month have not been established.

Duration of therapy for infantile spasms was evaluated in a post hoc analysis of a Canadian Pediatric Epilepsy Network (CPEN) study of developmental outcomes in infantile spasms patients. This analysis suggests that a total duration of 6 months of vigabatrin therapy is adequate for the treatment of infantile spasms. However, prescribers must use their clinical judgment as to the most appropriate duration of use [see Clinical Studies (14.2)] Abnormal MRI signal changes and Intramyelinic Edema (IME) in infants and young children being treated with vigabatrin have been observed [see Warnings and Precautions (5.3. 5.4)].

Juvenile Animal Toxicity Data Oral administration of vigabatrin (5, 15, or 50 mg/kg/day) to young rats during the neonatal and juvenile periods of development (postnatal days 4 to 65) produced neurobehavioral ulsions neuromotor impairment learning deficits) and neurohistonathological (brain gra

with plasma vigabatrin exposures (AUC) substantially less than those measured in pacific with the substantial plasma vigabatrin exposures (AUC) substantially less than those measured in pediatric dose for developmental neurotoxicity in juvenile rats (the lowest dose tested) was associated with plasma vigabatrin exposures (AUC) substantially less than those measured in pediatric diverse to a substantially less than those measured in pediatric diverse to a substantially less than those measured in pediatric diverse to a substantially less than those measured in pediatric diverse to a substantially less than those measured in pediatric diverse to a substantially less than those measured in pediatric diverse to a substantial diverse to a substantially less than those measured in pediatric diverse to a substantial diverse to a sub patients at recommended doses. In dogs, oral administration of vigabatrin (30 or 100 mg/kg/ day) during selected periods of juvenile development (postnatal days 22 to 112) produce eurohistopathological abnormalities (brain gray matter vacuolation). Neurobehavioral effects of vigabatrin were not assessed in the juvenile dog. A no-effect dose for neurohistopathology v not established in juvenile dogs; the lowest effect dose (30 mg/kg/day) was associated with plasma vigabatrin exposures lower than those measured in pediatric patients at recommended doses [see Warnings and Precautions (5.4)].

8.5 Geriatric Use Clinical studies of vigabatrin did not include sufficient numbers of patients aged 65 and over to determine whether they responded differently from younger patients. Vigabatrin is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Oral administration of a single dose of 1.5 g of vigabatrin to elderly (≥65 years) patients with reduced creatinine clearance (<50 mL/min) was associated with moderate to severe sedation and recubed clearing clearance (<20 intriming) was associated with indentate of severe second confusion in 4 of 5 patients, lasting up to 5 days. The renal clearance of vigabetrin was 38% lower in healthy elderly subjects (<265 years) than in young healthy males. Adjustment of dose frequency of administration should be considered. Such patients may respond to a lower maintenance dose [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. ent of dose or Other reported clinical experience has not identified differences in responses between the elderly

and vounger patients. 8.6 Renal Impairment

Does adjustment, including initiating treatment with a lower dose, is necessary in pediatric patients 2 years of age and older and adults with mild (creatinine clearance >50 to 80 mL/min), moderate (creatinine clearance >30 to 50 mL/min) and severe (creatinine clearance >10 to 80 mL/min), 30 mL/min) renal impairment *[see Dosage and Administration (<u>2.4</u>) and Clinical Pharmacology*

DRUG ABUSE AND DEPENDENCE

Controlled Substance batrin is not a controlled substance.

9.2 Abuse Vigabatrin did not produce adverse events or overt behaviors associated with abuse whe

dministered to humans or animals. It is not possible to predict the extent to which a CNS active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully valuate patients for history of drug abuse and follow such patients (closely, observing them for sign of misuse or abuse of vigabatrin (e.g., incrementation of dose, drug-seeking behavior). 9.3 Dependence

Following chronic administration of vigabatrin to animals, there were no apparent withdrawal signs upon drug discontinuation. However, as with all AEDs, vigabatrin should be withdrawn gradually to minimize increased seizure frequency [see Warnings and Precautions (5.6)]. 10 OVERDOSAGE

10.1 Signs, Symptoms, and Laboratory Findings of Overdosage Confirmed and/or suspected vigabatrin overdoses have been reported during clinical trials a post marketing surveillance. No vigabatrin overdoses resulted in death. When reported, the visco bit deap isopathet grant from 2 bit 0 and the mark two between 7.5 are add 0 a. M. ted during clinical trials and in abatrin dose ingested ranged from 3 g to 90 g, but most were between 7.5 g and 30 g. Nearly half the cases involved multiple drug ingestions including carbamazepine, barbit benzodiazepines, lamotrigine, valproic acid, acetaminophen, and/or chlorpheniramin


Coma, unconsciousness, and/or drowsiness were described in the majority of cases of vigabatrir overdose. Other less commonly reported symptoms included werigo, psychosis, apnea or respiratory depression, bradycardia, agitation, irritability, confusion, headache, hypotension, abnormal behavior, increased seizure activity, status epilepticus, and speech disorder. These symptoms resolved with supportive care.

10.2 Management of Overdosage There is no specific antidote for VIGADRONE overdose. Standard measures to remove unabsorbed drug should be used, including elimination by emesis or gastric lavage. Supportive measures should be employed, including monitoring of vital signs and observation of the clinical status of the patient.

In an in vitro study, activated charcoal did not significantly adsorb vigabatrin. The effectiveness of hemodialysis in the treatment of VIGADRONE overdose is unknown. In solated case reports in renal failure patients receiving therapeutic doses of vigabatrin. nodialysis reduced vigabatrin plasma concentrations by 40% to 60%.

DESCRIPTION VIGADRONE (vigabatrin, USP) is an oral antiepileptic drug and is available as a white to off-white granular powder for oral solution in packets of 500 mg.

The chemical name of vigabatrin, a racemate consisting of two enantiomers, is (\pm) 4-an 5-hexenoic acid. The molecular formula is $C_6H_{11}NO_2$ and the molecular weight is 129.16. It has the following structural formula:



Vigabatrin, USP is a white to off-white powder which is freely soluble in water, slightly soluble in viglicity and the constraint of the provided which is provided in the provided provided in the provided p dissociation constants (pK_a) of vigabatrin are 4 and 9.7 at room temperature (25°C). VIGADRONE powder for oral solution is available as white to off-white granular powder for oral administration. Each packet contains 500 mg of vigabatrin.

CLINICAL PHARMACOLOGY

Mechanism of Action The precise mechanism of vigabatrin's anti-seizure effect is unknown, but it is believed to be the result of its action as an irreversible inhibitor of γ -aminobutyric acid transaminase (GABA-T), the enzyme responsible for the metabolism of the inhibitory neurotransmitter GABA. This action results in increased levels of GABA in the central nervous system No direct correlation between plasma concentration and efficacy has been established. The

duration of drug effect is presumed to be dependent on the rate of enzyme re-synthesis rather than on the rate of elimination of the drug from the systemic circulation.

12.2 Pharmacodynamics Effects on Electrocardiogran

There is no indication of a QT/QTc prolonging effect of vigabatrin in single doses up to 6.0 g. In a randomized, placebo-controlled, crossover study, 58 healthy subjects were administered a sin oral dose of vigabatrin (3 g and 6 g) and placebo. Peak concentrations for 6.0 g vigabatrin we approximately 2-fold higher than the peak concentrations following the 3.0 g single oral dose. 12.3 Pharmacokinetics

atrin displayed linear pharmacokinetics after admini tration of single doses ranging from 0.5 g to 4 g, and after administration of repeated doses of 0.5 g and 2.0 g twice daily ence has been established between the oral solution and tablet formulations. The lowing PK information ($T_{\rm max}$, half-life, and clearance) of vigabatrin was obtained from PK studies and population PK analyses.

lowing oral administration, vigabatrin is essentially completely absorbed. The time to

maximum concentration (T_{max}) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age). There was little accumulation with multiple dosing in adult and pediatric patients. A food gc). There was not accompany with minimum momentum to the transmission of the statistic problem. A robust of the statistic problem is the statistic problem of the statist AUC was unchanged under fed conditions. Distribution Vigabatrin does not bind to plasma proteins. Vigabatrin is widely distributed throughout the

body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%) Metabolism and Elimination

Vigabatrin is not significantly metabolized; it is eliminated primarily through renal excretion. The terminal half-life of vigabatrin is about 5.7 hours for infants (5 months to 2 years of age), 6.8 hours for children (3 to 9 years of age), 9.5 hours for children and adolescents (10 to 16 years of age) and 10.5 hours for adults. Following administration of ^[14]C- vigabatrin to ealthy male volunteers, about 95% of total radioactivity was recovered in the urine over 72 hours with the parent drug representing about 80% of this. Vigabatrin induces CYP2C9 but does not induce other hepatic cytochrome P450 enzyme systems.

Specific Populations The renal clearance of vigabatrin in healthy elderly patients (>65 years of age) was 36% less than

those in healthy younger patients. This finding is confirmed by an analysis of data from a controlled clinical trial *[see Use in Specific Populations (8.5)]*.

The clearance of vigabatrin is 2.4 L/hr for infants (5 months to 2 years of age), 5.1 L/hr for children (3 to 9 years of age), 5.8 L/hr for children and adolescents (10 to 16 years of age) and 7 L/hr for adults.

No gender differences were observed for the pharmacokinetic parameters of vigabatrin in

lo specific study was conducted to investigate the effects of race on vigabatrir pharmacokinetics. A cross study comparison between 23 Caucasian and 7 Japanese patients who received 1, 2, and 4 g of vigabatrin indicated that the AUC, C_{max} , and half-life were similar r the two popu ations. However, the mean renal clearance of Caucasians (5.2 L/hr) was about % higher than the Japanese (4.0 L/hr). Inter-subject variability in renal clearance was 20% in asians and was 30% in Japanese

Aean AUC increased by 30% and the terminal half-life increased by 55% (8.1 hr vs 12.5 hr) in adult patients with mild renal impairment (CLcr from >50 to 80 mL/min) in comparison to normal subjects.

Mean AUC increased by two-fold and the terminal half-life increased by two-fold in adult patients vith moderate renal impairment (CLcr from >30 to 50 mL/min) in co

Mean AUC increased by 4.5-fold and the terminal half-life increased by 3.5-fold in adult patients with severe renal impairment (CLcr from >10 to 30 mL/min) in comparison to normal subjects Adult patients with renal impairment

Dosage adjustment, including starting at a lower dose, is recommended for adult patients with degree of renal impairment [see Use in Specific Populations (8.6) and Dosage and tration (2.4)] Infants with renal impairment

formation about how to adjust the dose in infants with renal impairment is unavailable. ediatric patients 2 years and older with renal impairmen Although information is unavailable on the effects of renal impairment on vigabatrin clearance in pediatric patients 2 years and older, dosing can be calculated based upon adult data and an established formula [see Use in Specific Populations (8.6) and Dosage and Administration (2.4)]. Henatic Imnairment

Vigabatrin is not significantly metabolized. The pharmacokinetics of vigabatrin in patients with impaired liver function has not been studied. Drug Interactions

A 16% to 20% average reduction in total phenytoin plasma levels was reported in adult A 10% to 20% average reduction in total prenyon plasma evers was reported in addition controlled clinical studies. *In vitro* drug metabolism studies indicate that decreased phenytoin concentrations upon addition of vigabatrin therapy are likely to be the result of induction of cytochrome P450 2C enzymes in some patients. Although phenytoin dose adjustments are not

routinely required, dose adjustment of phenytoin should be considered if clinically indicated [see Drug Interactions (7.1)

In a study of 12 healthy adult volunteers, clonazepam (0.5 mg) co-administration had no effect on vigabatrin (1.5 g twice daily) concentrations. Vigabatrin increases the mean C_{max} of clonazepam by 30% and decreases the mean T_{max} by 45% [see Drug Interactions (<u>7.1</u>)]. Other AEDs

When coadministered with vigabatrin, phenobarbital concentration (from phenobarbital o primidone) was reduced by an average of 8% to 16%, and sodium valproate plasma concentrations were reduced by an average of 8% to 16%. And sodium valproate plasma concentrations were reduced by an average of 8%. These reductions did not appear to be clinically relevant. Based on population pharmacokinetics, carbamazepine, clorazepate, primidone, and sodium valproate appear to have no effect on plasma concentrations of vioabatrin [see Drug Interactions (7.1)]. Alcohol

Coadministration of ethanol (0.6 g/kg) with vigabatrin (1.5 g twice daily) indicated that neither drug influences the pharmacokinetics of the other. Oral Contraceptives

bo-controlled study using a combination oral contraceptive cont n a double-blind, placeb 30 mcg ethinyl estradiol and 150 mcg levonorgestrel, vigabatrin (3 g/day) did not interfere significantly with the cytochrome P450 isoenzyme (CYP3A)-mediated metabolism of the ontraceptive tested. Based on this study, vigabatrin is unlikely to affect the efficacy of steroid contraceptive tested. Based on this study, vigabilitin's unitary to affect the efficacy of stellour oral contraceptives. Additionally, no significant difference in pharmacokinetic parameters (elimination half-life, AUC, C_{max}, apparent oral clearance, time to peak, and apparent volume or distribution) of vigabatrin were found after treatment with ethinyl estradiol and levonorgestrel [see Drug Interactions (7.2)].

NONCLINICAL TOXICOLOGY

1 Carcinogenesis, Mutagenesis, Impairment of Fertility abatrin showed no carcinogenic potential in mouse or rat when given in the diet at doses up 150 mg/kg/day for 18 months (mouse) or at doses up to 150 mg/kg/day for 2 years (rat), use doses are less than the maximum recommended human dose (MRHD) for infantile additional dose (MRHD) for infantile dose (MRHD) for infantile dose (MRHD). spasms (150 mg/kg/day) and for refractory complex partial seizures (3 g/day) on a mg/m² basis. Vigabatrin was negative in in vitro (Ames, CHO/HGPRT mammalian cell forward gene mutation, nosomal aberration in rat lymphocytes) and in *in viv*o (mouse bone marrow micronucleus

No adverse effects on male or female fertility were observed in rats at oral doses up to 50 mg/kg/day (approximately ½ the MRHD of 3 g/day on a mg/m² basis for refractory compl partial seizures).

CLINICAL STUDIES 14.1 Complex Partial Seizures

The effectiveness of vigabatrin as adjunctive therapy in adult patients was established in two U.S. multicenter, double-blind, placebo-controlled, parallel-group clinical studies. A total of 357 adults (age 18 to 60 years) with complex partial seizures, with or without secondary generalization were enrolled (Studies 1 and 2). Patients were required to be on an adequate and stable dose of mere enforced victories 1 and 2), Faterier swere required to be on an adequate and state dose to an anticonvulsant and have a history of failure on an adequate regimen of carbamazepine or phenytoin. Patients had a history of about 8 seizures per month (median) for about 20 years (median) prior to entrance into the study. These studies were not capable by design of demonstrating direct superiority of vigabatrin over any other anticonvulsant added to a regimen to which the patient had not adequately responded. Further, in these studies, patients had previously been treated with a limited range of anticonvulsants.

The primary measure of efficacy was the patient's reduction in mean monthly frequency of nplex partial seizures plus partial seizures secondarily generalized at end of study compare


Study 1 (N=174) was a randomized, double-blind, placebo-controlled, dose-response study consisting of an 8-week baseline period followed by an 18-week treatment period. Patients were randomized to receive placebo or 1, 3, or 6 g/day vigabatrin administered twice daily. During the first 6 weeks following randomization, the dose was titrated upward beginning with 1 g/day and increasing by 0.5 g/day on days 1 and 5 of each subsequent week in the 3 g/day and 6 g/day groups, until the assigned dose was reached.

Results for the primary measure of effectiveness, reduction in monthly frequency of comple partial seizures, are shown in Table 8. The 3 g/day and 6 g/day dose groups were statisticall significantly superior to placebo, but the 6 g/day dose was not superior to the 3 g/day dose. Table 8. Median Monthly Frequency of Complex Partial Sei

Table 6. Median Monthly Frequency of Complex Farital Seizures+				
	Ν	Baseline	Endstudy	
Placebo	45	9.0	8.8	
1 g/day Vigabatrin	45	8.5	7.7	
3 g/day Vigabatrin	41	8.5	3.7*	
6 g/day Vigabatrin	43	8.5	4.5*	
* p<0.05 compared to placebo				

Including one patient with simple partial seizures with secondary generalization only Figure 1 presents the percentage of patients (X-axis) with a percent reduction in seizure requency (responder rate) from baseline to the maintenance phase at least as great as that represented on the Y-axis. A positive value on the Y-axis indicates an improvement from baselin (i.e., a decrease in complex partial seizure frequency), while a negative value indicates a worsening from baseline (i.e., an increase in complex partial seizure frequency). Thus, in a display of this type, a curve for an effective treatment is shifted to the left of the curve for placebo. The proportion of patients achieving any particular level of reduction in complex partia pacebo rine proportion of patients achieving any particulation rever of reduction in consistently higher for the vigabatrin 3 and 6 g/day groups compared to the placebo group. For example, 51% of patients randomized to vigabatrin 3 g/day and 53% of patients randomized to vigabatrin 6 g/day experienced a 50% or greater reduction in seizure quency, compared to 9% of patients randomized to placebo. Patients with an increase in seizure frequency >100% are represented on the Y-axis as equal to or greater than -100%

Figure 1. Percent Reduction from Baseline in Seizure Frequency



3 g/day Vigabatrin

p<0.05 compared to placebo

as equal to or greater than -100%.

Pediatric patients 3 to 16 years of age

14.2 Infantile Spasms

Study 2 (N=183 randomized, 182 evaluated for efficacy) was a randomized, double-blind, placebo-controlled, parallel study consisting of an 8-week baseline period and a 16-week treatment period. During the first 4 weeks following randomization, the dose of vigabatrin was titrated upward beginning with 1 g/day and increased by 0.5 g/day on a weekly basis to the enance dose of 3 g/day. Results for the primary measure of effectiveness, reduction in monthly complex partial seizure

frequency, are shown in Table 9. Vigabatrin 3 g/day was statistically significantly superior to placebo in reducing seizure frequency. Table 9. Median Monthly Frequency of Complex Partial Seizures

Figure 2 presents the percentage of patients (X-axis) with a percent reduction in seizure

(i.e., a decrease in complex partial seizure frequency), while a negative value indicates a worsening from baseline (i.e., an increase in complex partial seizure frequency). Thus, in display of this type, a curve for an effective treatment is shifted to the left of the curve for the set of the

placebo. The proportion of patients achieving any particular level of reduction in seizure

frequency was consistently higher for the vigabatrin 3 g/day group compared to the placeb

group. For example, 39% of patients randomized to vigabatrin (3 g/day) experienced a 50% or greater reduction in complex partial seizure frequency, compared to 21% of patients randomize to placebo. Patients with an increase in seizure frequency >100% are represented on the Y-axis or aguel be a greater than 100%

Figure 2. Percent Reduction from Baseline in Seizure Frequency

For both studies, there was no difference in the effectiveness of vigabatrin between male and

female patients. Analyses of age and race were not possible as nearly all patients were betwee the ages of 18 to 65 and Caucasian.

269 patients who received vigabatrin and 104 patients who received placebo. No individual study was

considered adequately powered to determine efficacy in pediatric patients age 3 years and above. The data from all three pediatric studies were pooled and used in a pharmacometric bridging analysis using weight-normalized doses to establish efficacy and determine appropriate dosing. All three

studies were randomized, double-blind, placebo-controlled, parallel-group, adjunctive-treatment studies in patients aged 3 to 16 years with uncontrolled complex partial seizures with or without

The pharmacometric bridging approach consisted of defining a weight-normalized dose-re

these pharmacometric dose-response analyses [see Dosage and Administration (2.2)]

17 week treatment phase (composed of a titration and maintenance period

ndary generalization. The study period included a 6 to 10 week baseline phase and a 14 to

and showing that a similar dose-response relationship exists between pediatric patients and adul patients when vigabatrin was given as adjunctive therapy for complex partial seizures. Dosing

recommendations in pediatric patients 2 to 16 years of age were derived from simulations utilizin

The effectiveness of vigabatrin as monotherapy was established for infantile spasms in two multicenter controlled studies. Both studies were similar in terms of disease characteristics and prior treatments of patients and all enrolled infants had a confirmed diagnosis of infantile spasms.

<u>Study 1</u> Study 1 (N=221) was a multicenter, randomized, low-dose high-dose, parallel-group, partially-

Study 1 (w=221) was a finited that, failoutined, low-dose ingir-lose, parallel-group, parallel

randomized to receive either low-dose (18 to 36 mg/kg/day) or high-dose (100 to 148 mg/kg/day) vigabatrin. Study drug was tirtated over 7 days, followed by a constant dose for 7 days. If the patient became spasm-free on or before day 14, another 7 days of constant dose was administered. The primary efficacy endpoint of this study was the proportion of patients who were spasm-free for 7 consecutive days beginning within the first 14 days of vigabatrin therapy. Patients considered spasm-free were defined as those patients who remained free of

Spasms (evaluated according to caregiver response to direct questioning regarding spasm frequency) and who had no indication of spasms or hypsarrhythmia during 8 hours of CCTV EEG recording (including at least one sleep-wake-sleep cycle) performed within 3 days of the seventh day of spasm freedom and interpreted by a blinded EEG reader. Seventeen patients in the high-dose group achieved spasm freedom compared with 8 patients in the low dose group. This difference was statistically significant (p=0.0375). Primary efficacy results are shown in Table 10.

nized to receive either low-dose (18 to 36 mg/kg/day) or high-dose (100 to

spasms (evaluated according to caregiver response to direct questioning regarding spasm

gabatrin was studied in three double-blind, placebo-controlled, parallel-group studies in

on the Y-axis A positive value on the Y-axis indi

ency (responder rate) from baseline to the maintenance phase at least as great as that

Baseline

9.0

8.3

Endstudy

Placebo 3g/dayVGB

	Vigabatrin Trea 18 to 36 mg/kg/day	atment Group 100 to 148 mg/kg/day
	[N=114] n (%)	[N=107] n (%)
ients who Achieved Spasm edom .0375	8 (7.0)	17 (15.9)
e: Primary criteria were evaluated bas firmation within 3 days of the seventh <u>dy 2</u>		nt plus CCTV EEG
dy 2 (M=40) was a multicenter, randor by consisting of a pre-treatment (base bie-blind treatment phase during white mg/kg/day with titration allowed to 15 its study was the average percent cha defined and consistent 2-hour window ne 5-day double-blind treatment phase e average frequency of spasms using rnative efficacy analysis, using a 24-h- hificant difference in the overall percen pp (68.9%) and the placebo group (17 ation of therapy for infantile spasms v iatric Epilepsy Network (CPEN) study ents. The 38/68 infants in the study w sation of spasms and hypsarrhythmia onths therapy. The 38 infants who res	line) period of 2 to 3 days, ch patients were treated wi 0 mg/kg/day) or placebo. 1 nge in daily spasm frequer w of evaluation, comparing e. No statistically significar (the 2-hour evaluation win our clinical evaluation win our clinical evaluation win our clinical evaluation win vas evaluated in a post hoo of developmental outcome ho had responded to vigat) continued vigabatrin ther	followed by a 5-day th vigabatrin (initial dose of the primary efficacy endpoint tcy, assessed during a baseline to the final 2 days at differences were observed dow. However, a post-hoc low found a statistically ms between the vigabatrin analysis of a Canadian is in infantile spasms latin therapy (complete apy for a total duration of
nonths after discontinuation of vigaba ysis indicated no observed recurrence	e of infantile spasms in any	
HOW SUPPLIED/STORAGE AND H 1 How Supplied ADRONE [®] powder for oral solution, 5 /der. They are supplied in cartons of 5	00 mg packets contain a w	
oral syringes are provided separately		
2 Storage and Handling re at 20° to 25°C (68° to 77°F). [See L PATIENT COUNSELING INFORMAT		perature].
vise patients and caregivers to read the tructions for Use).	e FDA-approved patient lab	
ninistration Instructions for VIGADRO rsicians should confirm that caregiver ution and to administer the correct do Administration (2.5)].	(s) understand how to mix	VIGADRONE for Oral
<u>manent Vision Loss</u> rm patients and caregivers of the risk on, from VIGADRONE, and the need fo		
()). nitoring of vision, including assessme eline (no later than 4 weeks after start 'apy, and about 3 to 6 months after dis ing is not possible, treatment may cor ical judgment with appropriate patient	ing VIGADRONE), at least scontinuation of therapy. In ntinue without recommend t or caregiver counseling. F	every 3 months while on n patients for whom vision ed testing according to Patients or caregivers should
informed that if baseline or subsequen d if the benefits of VIGADRONE treatrr vise patients and caregivers that vision s before it is severe. Also advise patier h loss is irreversible. Ensure that both egivers.	nent clearly outweigh the ri I testing may be insensitive Its and caregivers that if vi	sks of additional vision loss. and may not detect vision sion loss is documented,
ients and caregivers should be informe ify their physician immediately.	ed that if changes in vision	are suspected, they should
abatrin REMS Program ADRONE is available only through a re <i>e Warnings and Precautions (<u>5.2</u>)].</i> Inf Patients/caregivers must be enrolled VIGADRONE is only available throug	form patients/caregivers of in the program.	the following:
Program. <u>I Abnormalities in Infants</u> prm caregiver(s) of the possibility that	infants may develop an ab	normal MRI signal of
known clinical significance <i>[see Warnir</i> cidal Thinking and Behavior		
Insel patients, their caregiver(s), and fan of suicidal thoughts and behavior. Also emergence or worsening of symptoms he emergence of suicidal thoughts, beha uld be reported immediately to healthca gnancy	advise patients and caregiv of depression, any unusual avior, or thoughts of self-ha	ers of the need to be alert for changes in mood or behavior, rm. Behaviors of concern
ise pregnant women and women of cl ing pregnancy can cause fetal harm w w they are pregnant. Instruct patients nd to become pregnant during therapy istry that collects information about th in Specific Populations (<u>8.1</u>).	hich may occur early in pro to notify their physician if y. Advise patients that ther	egnancy before many women they become pregnant or e is a pregnancy exposure
sing Insel patients that VIGADRONE is excr erese reactions in nursing infants from ision is made to breastfeed, nursing m ns of vision loss, sedation and poor su <u>hdrawal of VIGADRONE Therapy</u>	VIGADRONE, breastfeedin nothers should be counseled ucking [see Use in Specific	ig is not recommended. If a ed to observe their infants for <i>Populations (<u>8.2</u>)].</i>
truct patients and caregivers not to sur- sulting with their healthcare provider. dual [see Warnings and Precautions (<u>see Warnings</u> and Precautions (see Patients)]	As with all AEDs, withdraw	RONE therapy without val should normally be
nufactured for SHER-SMITH LABORATORIES, LLC ple Grove, MN 55369		
ADRONE is a registered trademark of de in Germany	Upsher-Smith Laboratorie	
556AU		Revised 0220
VIGADRO	CATION GUIDE NE® (vi-ga-drōr	ie)
	rigabatrin) for oral solution	n
/hat is the most impor bout VIGADRONE?	tant informatior	ı I should know
IGADRONE can cause Permanent vision los Magnetic resonance babies with infantile	ss imaging (MRI) spasms (IS)	, c
Risk of suicidal thou Permanent vision los	5	
IGADRONE can damag	e the vision of a	
. Some people can have bility to see to the side		
peripheral vision). With	severe vision lo	ss, you may
nly be able to see thing sometimes called "tunn		
urry vision. If this happ		
Vision loss and use of children 2 years and vision loss, VIGADRO	older: Because	of the risk of

partial seizures (CPS) only in people who do not respond well enough to several other medicines.

- Tell your healthcare provider right away if you (or your child) might not be seeing as well as before starting
- VIGADRONE • start to trip, bump into things, or are more clumsy
- than usual • are surprised by people or things coming in front
- of you that seem to come out of nowhere • These changes can mean that you (or your child) have damage to your vision.
- It is recommended that your healthcare provider test your (or your child's) vision (including peripheral vision) and visual acuity (ability to read an eye chart) before you (or your child) start VIGADRONE or within 4 weeks after starting VIGADRONE, and at least every 3 months after that until VIGADRONE is stopped. It is also recommended that you (or your child) have a vision test about 3 to 6 months after VIGADRONE is stopped. Your vision loss may get
- worse after you stop taking VIGADRONE. • Some people are not able to complete testing of vision. Your healthcare provider will determine if you (or your child) can be tested. If you (or your child) cannot complete vision testing, your healthcare provider may continue prescribing VIGADRONE, but your healthcare provider will not be able to watch for any vision loss you (or your

child) may get.

- Even if your vision (or your child's vision) seems fine, it is important that you (or your child) get these regular vision tests because vision damage can happen before you (or your child) notice any
- changes. These vision tests cannot prevent the vision damage that can happen with VIGADRONE, but they do allow the healthcare provider to decide if vou (or vour child) should stop VIGADRONE if vour vision has gotten worse.
- Vision testing may not detect vision loss before it is severe.
- If you do not have these vision tests regularly, your healthcare provider may stop prescribing VIGADRONE.
- If you drive and your vision is damaged by VIGADRONE, driving might be more dangerous, or you may not be able to drive safely at all. Talk
- about this with your healthcare provider. Vision loss in babies: Because of the risk of vision loss, VIGADRONE is used in babies 1 month to 2 years of age with infantile spasms (IS) only when you and your healthcare provider decide that the possible benefits of VIGADRONE are more important than the risks
- Parents or caregivers are not likely to recognize the symptoms of vision loss in babies until it is severe. Healthcare providers may not find vision loss in
- babies until it is severe. It is difficult to test vision in babies, but, to the extent possible, all babies should have their vision tested before starting VIGADRONE or within 4 weeks after starting VIGADRONE, and every 3 months after that until VIGADRONE is stopped. Your baby should also have a vision test about 3 to 6 months after VIGADRONE is stopped.
- Your baby may not be able to be tested. Your healthcare provider will determine if your baby can be tested. If your baby cannot be tested, your healthcare provider may continue prescribing VIGADRONE, but your healthcare provider will not be able to watch for any vision loss.

l your healthcare provider right away if you think at your baby is:

- not seeing as well as before taking VIGADRONE acting differently than normal • Even if your baby's vision seems fine, it is
- important to get regular vision tests because damage can happen before your baby acts differently. Even these regular vision exams may not show the damage to your baby's vision before it is severe and permanent.
- All people who take VIGADRONE: • You are at risk for permanent vision loss
- with any amount of VIGADRONE. • Your risk of vision loss may be higher
- the more VIGADRONE you take daily and the longer you take it. It is not possible for your healthcare
- provider to know when vision loss will happen. It could happen soon after starting VIGADRONE or any time during treatment. It may even happen aftei treatment has stopped.
- Because VIGADRONE might cause permanent vision loss, it is available to healthcare providers and patients only under a special program called the Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) Program. VIGADRONE can only be prescribed to people who are enrolled in this program. As part of the Vigabatrin REMS Program, it is recommended that your healthcare provider test your (or your child's) vision from time to time (periodically) while you (or your child) are being treated with VIGADRONE, and even after you (or your child) stop treatment. Your healthcare provider will explain the details of the Vigabatrin REMS Program to you. For more information, go to www.vigabatrinREMS.com or call 1-866-244-8175.

Magnetic resonance imaging (MRI) changes in babies with infantile spasms: ain pictures taken by magnetic resonance imaging

(MRI) show changes in some babies after they are given VIGADRONE. It is not known if these changes are harmful. 3. Risk of suicidal thoughts or actions: Like other antiepileptic drugs, VIGADRONE may cause

suicidal thoughts or actions in a very small number of people, about 1 in 500 people taking it. Call a healthcare provider right away if you or your child have any of these symptoms, especially if they are new, worse, or worry

- thoughts about suicide or dying attempts to commit suicide
- new or worse depression
- new or worse anxiety
- feeling agitated or restless • panic attacks
- trouble sleeping (insomnia)
- new or worse irritability
- acting aggressive, being angry, or violent
- acting on dangerous impulses

• an extreme increase in activity and talking (mania) other unusual changes in behavior or mood Suicidal thoughts or actions can be caused by things other than medicines. If you or your child have suicidal thoughts or actions, your healthcare provider may check

for other causes. How can I watch for early symptoms of suicidal

thoughts and actions? • Pay attention to any changes, especially sudden

changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled.

- attempts at suicide
- are pregnant or plan to become pregnant. VIGADRONE can cause harm to your unborn baby. You and your healthcare provider will have to decide if

American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. Information on the registry can also be found at the website http://www.aedpregnancy.org/. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy.

before giving VIGADRONE to your baby, tell your healthcare provider about all of your baby's medical

conditions, including if your baby has or ever had: • an allergic reaction to VIGADRONE, such as hives. itching, or trouble breathing

• any vision problems any kidney problems

Tell your healthcare provider about all the medicines you or your child take, including prescription and overthe-counter medicines, vitamins, and herbal supplements. VIGADRONE and other medicines may affect each other causing side effects. How should I take VIGADRONE?

- You or your child will receive VIGADRONE from a specialty pharmacy. Take VIGADRONE exactly as your healthcare provider
- tells you to. VIGADRONE is usually taken 2 times each | |com or call 1-888-650-3789. • VIGADRONE may be taken with or without food.
- Before starting to take VIGADRONE, talk to your healthcare provider about what you or your child should do if a VIGADRONE dose is missed. If you or your child are taking VIGADRONE for CPS
- and the seizures do not improve enough within 3 months, your healthcare provider will stop prescribing VIGADRONE
- If your child is taking VIGADRONE for IS and the seizures do not improve within 2 to 4 weeks, your healthcare provider will stop prescribing VIGADRONE.
- **Do not stop taking VIGADRONE suddenly.** This can cause serious problems. Stopping VIGADRONE or any seizure medicine suddenly can cause seizures that will not stop (status epilepticus) in people who are being treated for seizures. You should follow your healthcare provider's instructions on how to stop
- taking VIGADRONE Tell your healthcare provider right away about any increase in seizures when VIGADRONE treatment is **being stopped.** Before your child starts taking VIGADRONE, speak to your child's healthcare provider about what to do if your baby misses a dose, vomits,
- spits up, or only takes part of the dose of VIGADRONE. • Do not stop taking VIGADRONE without talking to your healthcare provider. If VIGADRONE improves your (or your child's) seizures, you and your healthcare provider should talk about whether the
- benefit of taking VIGADRONE is more important than the risk of vision loss and decide if you (or your child) will continue to take VIGADRONE • If you are giving VIGADRONE powder for oral solution
- to your child, it can be given at the same time as their meal. VIGADRONE for oral solution powder should be mixed with water only. • See "Instructions for Use" for detailed information
- about how to mix and give VIGADRONE powder for oral solution to your child the right way.

mixed

nerve problems. Symptoms of a nerve problem can include numbness and tingling in your toes or feet. It is not known if nerve problems will go away after you stop taking VIGADRONE. swelling

linclude:

What should I tell my healthcare provider before starting VIGADRONE? If you or your child has CPS, before taking VIGADRONE

tell your healthcare provider about all of your medical conditions, including if you or your child: • have or had an allergic reaction to VIGADRONE, such

as hives, itching, or trouble breathing have or had any vision problems

• Call your healthcare provider between visits as

needed, especially if you are worried about

people who are being treated for seizures.

• Do not stop VIGADRONE without first talking to a

Stopping VIGADRONE suddenly can cause serious

problems. Stopping a seizure medicine suddenly can

VIGADRONE is a prescription medicine used along with

other treatments to treat adults and children 2 years

and older with complex partial seizures (CPS) if:

• the CPS do not respond well enough to several

• you and your healthcare provider decide the

important than the risk of vision loss.

than the possible risk of vision loss.

possible benefit of taking VIGADRONE is more

VIGADRONE should not be the first medicine used to

VIGADRONE is also used to treat babies 1 month to

2 years of age who have infantile spasms (IS) if you

benefits of taking VIGADRONE are more important

and your healthcare provider decide the possible

cause seizures that will not stop (status epilepticus) in

symptoms

healthcare provider.

What is VIGADRONE?

treat CPS.

other treatments, **and**

- have or had any kidney problems have or had low red blood cell counts (anemia) have or had any nervous or mental illnesses, such as
- depression, mood problems, thoughts of suicide, or are breastfeeding or planning to breastfeed.
- VIGADRONE can pass into breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take VIGADRONE.

vou should take VIGADRONE while you are pregnant.

Pregnancy Registry: If you become pregnant while taking VIGADRONE, talk to your healthcare provider about registering with the North

If you are a parent or caregiver whose baby has IS,

What should I avoid while taking VIGADRONE? VIGADRONE causes sleepiness and tiredness. Adults taking VIGADRONE should not drive, operate machinery, or perform any hazardous task, unless you and your healthcare provider have decided that you can do these things safely. What are the possible side effects of VIGADRONE? VIGADRONE can cause serious side effects, including:

See "What is the most important information I should know about VIGADRONE?" sleepiness and tiredness. See "What should I avoid while taking VIGADRONE?" VIGADRONE may cause your baby to be sleepy.

Sleepy babies may have a harder time suckling and feeding or may be irritable. weight gain that happens without swelling

The following serious side effects happen in **adults**. It is not known if these side effects also happen in babies who take VIGADRONE.

Iow red blood cell counts (anemia)

If you or your child has CPS, VIGADRONE may make certain types of seizures worse. Tell your healthcare provider right away if your (or your child's) seizures get worse. The most common side effects of VIGADRONE in **adults**

include blurred vision, sleepiness, dizziness, problems walking or feeling uncoordinated, shaking (tremor) and tiredness. The most common side effect of VIGADRONE in children **3 to 16 years of age** is weight gain. Also expect side effects like those seen in adults.

If you are giving VIGADRONE to your baby for IS: VIGADRONE may make certain types of seizures worse.

You should tell your baby's healthcare provider right away if your baby's seizures get worse. Tell your baby's healthcare provider if you see any changes in your baby's behavior. The most common side effects of VIGADRONE in **babies**

• sleepiness – VIGADRONE may cause your baby to be sleepy. Sleepy babies may have a harder time suckling and feeding or may be irritable. • swelling in the bronchial tubes (bronchitis) ear infection

 irritability Tell your healthcare provider if you or your child have any side effect that bothers you or that does not go away. These are not all the possible side effects of VIGADRONE.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store VIGADRONE? • Store VIGADRONE packets at room temperature

between 20° to 25°C (68° to 77°F). Keep VIGADRONE and all medicines out of the reach of children.

General information about the safe and effective use of VIGADRONE

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about VIGADRONE that is written for health professionals. Do not use VIGADRONE for a condition for which it was not

prescribed. Do not give VIGADRONE to other people, even if they have the same symptoms that you have. It may harm them.

What are the ingredients in VIGADRONE? Active Ingredient: vigabatrin

For Medication Guides, please visit www.upsher-smith.

Manufactured for UPSHER-SMITH LABORATORIES, LLC

Made in Germany

Maple Grove, MN 55369 VIGADRONE is a registered trademark of Upsher-Smith Laboratories, LLC.

This Medication Guide has been approved by the U.S. Food and Drug Administration. IN0556AU Revised 0220

INSTRUCTIONS FOR USE

VIGADRONE[®] (vi-ga-drōne) (vigabatrin)

Powder for oral solution Read this Instructions for Use before your child starts taking VIGADRONE and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your child's medical condition or treatment. Talk to your healthcare provider if you have any questions about the right dose of medicine to give your child or how to mix it.

Important Note: • VIGADRONE comes in a packet • Each packet contains 500 mg of VIGADRONE

powder • VIGADRONE powder must be mixed with water only. The water may be cold or at room temperature. • Your healthcare provider will tell you:

 how many packets of VIGADRONE you will need for each dose • how many milliliters (mL) of water to use to mix

one dose of VIGADRONE • how many milliliters (mL) of the powder and water mixture you will need for each dose of

medicine • VIGADRONE should be given right away after it is

• Use the oral syringes, provided by the pharmacy, to measure and give the correct dose. Do not use a household teaspoon or tablespoon.

Supplies you will need to mix 1 dose of VIGADRONE:



- The number of packets of VIGADRONE needed for each dose • 2 clean cups: 1 for mixing and 1 for water. The cup used for mixing VIGADRONE should be clear so you can see if the powder is dissolved
- Water to mix with the VIGADRONE powder • One small 3 mL oral syringe and one large 10 mL oral syringe which are provided by the pharmacy.
- Small spoon or other clean utensil to stir the mixture Scissors



Step 1: Start with **1** of the empty cups and the total number of packets you will need for 1 dose. **Step 2**: Before you open the packet, tap it to settle all the powder to the bottom of the packet. **Step 3**: Use a pair of scissors to cut open the VIGADRONE packet along the dotted line.

Step 4: Empty the entire contents of the VIGADRONE packet into **1** of the clean empty cups (see Figure A).



Figure A • Repeat steps 2 to 4 above to open all of the packets needed for 1 dose of VIGADRONE. Step 5: Take the second cup and fill it half way with water (see Figure B).

Do not mix VIGADRONE with anything other than water.



Figure B

• You will use the **larger** oral syringe (10 mL) to draw up the water needed to mix with the powder from the packets. You will need 10 mL of water for each packet of VIGADRONE. For example:

- If you are using 1 packet of VIGADRONE, you will need to use 10 mL of water (fill the 10 mL oral syringe 1 time)
- If you are using 2 packets of VIGADRONE, you will need to use 20 mL of water (fill the 10 mL oral syringe 2 times)
- If you are using 3 packets of VIGADRONE, you will need to use 30 mL of water (fill the 10 mL oral syringe 3 times)

Step 6: Use the 10 mL oral syringe to draw up 10 mL of water. To do this, put the **tip** of the oral syringe all the way into the water in your cup. Then pull the plunger up towards you until the edge of the white plunger is at the 10 mL line on the barrel of the oral syringe (see Figure C).



Figure C

• If you see bubbles of air in the oral syringe after drawing up the water, turn the oral syringe so the tip is pointing up (see Figure D). The air will move to the top of the oral syringe. Pull the plunger back towards you and then push it back gently into the oral syringe to get rid of the bubbles. Tiny bubbles are normal.



Step 7: Check the oral syringe to make sure it is filled with water up to the 10 mL line (see Figure E).



Figure E

Step 8: Get the second cup that contains the VIGADRONE needed for your dose. **Step 9**: Hold the 10 mL oral syringe that is filled with water with the tip pointing down over the VIGADRONE. **Step 10: Slowly** push the oral syringe plunger all the way down to empty the water from the oral syringe straight




Figure F

Repeat steps 6 through 10 until all of the water that is needed to mix 1 dose of VIGADRONE has been added to the cup containing the powder. **Step 11**: Stir the mixture with the small spoon or other

clean utensil until the solution is clear (see Figure G). This means that all of the powder is dissolved and ready for use.



Figure G

- To give a dose of VIGADRONE to your child, you should use the oral syringe to draw up the total number of mLs of the mixture that your healthcare provider tells you to.
- If you are giving **3 mL or less** of the mixture, use the smaller 3 mL oral syringe.
- If you are giving more than 3 mL of the mixture, use the larger 10 mL oral syringe (this is the oral syringe that you just used to add the water).

Step 12: Put the tip of the oral syringe all the way into the mixture. Pull the plunger up towards you to draw up the mixture. Stop when the edge of the white plunger lines up with the markings on the barrel of the oral syringe that matches the number of mLs of mixture your healthcare provider told you to give (see Figure H).



Figure H

• If you see bubbles of air in the oral syringe after drawing up the mixture, turn the oral syringe so the tip is pointing up (see Figure I). The air will move to the top of the oral syringe. Pull the plunger back towards you and then gently push it back in the oral syringe in order to get rid of the bubbles. Tiny bubbles are normal.



Figure I

Step 13: Place the tip of the oral syringe into your child's mouth and point the oral syringe towards either cheek (see Figure J). Push on the plunger slowly, **a small amount at a time**, until all of the mixture in the oral syringe is given.



Figure J

• If the dose you are giving your child is more than 10 mLs, repeat steps 12 and 13 until you give the total dose of mixture prescribed by your healthcare provider.

Step 14: Throw away any mixture that is left over. Do not save or reuse any leftover mixture. **Step 15**: Wash the oral syringes and mixing cups in warm water. To clean the oral syringes, remove the plunger by gently pulling it straight out of the barrel. The barrel and plunger can be hand washed with soap and water, rinsed, and allowed to dry.

For Instructions for Use, please visit www.upsher-smith.com or call 1-888-650-3789.

This Instructions for Use has been approved by the U.S. Food and Drug Administration. Manufactured for

UPSHER-SMITH LABORATORIES, LLC

Maple Grove, MN 55369 VIGADRONE is a registered trademark of Upsher-Smith Laboratories, LLC. Made in Germany IN0556AU

PM-000018.02

© 2020 Upsher-Smith Laboratories, LLC

Revised 0220